réutilisable, le concevoir avec des bio-résines et limiter le nombre de pièces au maximum. Quelles sont justement les grandes tendances qui se dessinent sur ce marché à travers les demandes de vos clients ? C.G.: La demande de sustainability dans les dispositifs est effectivement une des tendances. Beaucoup de clients nous demandent d’être accompagnés dans cette démarche. C’est pourquoi Nemera a mis en place un partenariat afin d’être un interlocuteur crédible Symbioze a été spécialement conçu pour les médicaments tels que les thérapies biologiques.® et les conseiller dans leur approche de C’est un dispositif porté réutilisable adapté aux grands volumes d’injection de 20 ml et plus. réduction de leur empreinte carbone. Symbioze has been specially designed for drugs such as biological therapies. It is a reusable,® Mais la tendance la plus forte se situe wearable device suitable for large injection volumes of 20 ml and more. dans la demande de plateforme de dis- positifs d’administration parentérale. phase avec notre stratégie de dévelop- Différentes approches peuvent être Auparavant, les grands laboratoires pement durable et faire progresser la conjuguées au niveau de cette plate- étaient plutôt enclins à développer réduction de notre empreinte carbone. forme : rendre une partie du dispositif leur propre système d’administration. Is the launch of a reusable What are the major trends manufacturers and biotechs. They do not auto-injector platform in emerging in this market as have R&D departments large enough to response to a request from a result of your customers' design their own systems. What's more, your customers? requests? by using a manufacturer like Nemera, they can speed up their time-to-market, C.G.: The disposable auto-injector C.G.: The demand for ‘sustainability’ in benefit from economies of scale and have segment is currently dominated by two devices is indeed one of the trends. A lot a consistent range if they offer different manufacturers who have been present of our customers are asking us for sup- molecules. This demand for injection in this market since the 1990s. Nemera port in this area. For this reason, Nemera platforms also corresponds to a need didn't offer any products until then. After has set up a partnership in order to be for injection volumes greater than those studying this market, we decided to focus a credible partner and advise them in currently available. In fact, the current all our efforts on a reusable device in their approach to reducing their carbon transfer of treatments administered order to be in line with our sustainable footprint. But the strongest trend is in intravenously to the subcutaneous route development strategy and make progress the demand for platforms for parenteral requires reformulation, most often invol- in reducing our carbon footprint. Different administration devices. Previously, the ving an increase in the volume of the approaches can be combined for this plat- major pharmaceutical companies were dose to be injected. Treatments for rare form: making part of the device reusable, more inclined to develop their own admi- diseases based on biological products designing it with bio-resins and keeping nistration systems. Now we are seeing are also often characterised by injection the number of parts to a minimum. the opposite, particularly from generic volumes that far exceed those previously October - 2024 / The Pharmaceutical Post 20 45 WEIVRETNI